Search Results

The American Diabetes Association ® announced the winners of its Innovation Challenge competition. Innovators showcased novel ideas for diabetes care before a panel of potential funders and an audience of professionals in the field, with the goal of furthering transformative solutions for people living with diabetes, their families, and caregivers.

New developments for early risk monitoring of Type 1 Diabetes (T1D) were presented as part of the American Diabetes Association’s® (ADA) 84th Scientific Sessions in Orlando, FL.

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, announced its schedule of presentations for the American Diabetes Association’s 84th Scientific Sessions taking place in Orlando, Florida from June 21-24.

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that results from the prevalence phase of its CATALYST study of hypercortisolism (Cushing’s syndrome) in patients with difficult-to-control type 2 diabetes were presented at the American Diabetes Association’s 84th Scientific Sessions.

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, presented new real-world insights from a survey on Tandem Mobi user satisfaction and wearability during the 84th Scientific Sessions of the American Diabetes Association taking place in Orlando, Florida.

Veru Inc. announced that the Company will present two presentations at the American Diabetes Association’s 84th Scientific Sessions, taking place June 21-24, 2024, in Orlando, Florida.

Senseonics Holdings, Inc. announced plans to host a business update and analyst event during the American Diabetes Association’s 84th Scientific Sessions in Orlando, FL.

Altimmune, Inc. today announced oral presentations on pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH, at the American Diabetes Association’s (ADA) 84th Scientific Sessions, to be held in Orlando, FL from June 21-24, 2024.

Trinity Biotech plc, a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, announces that its senior management team plans to attend the 84th Scientific Sessions of the American Diabetes Association in Orlando Florida, taking place on June 21-24, 2024.

Gan & Lee Pharmaceuticals announced the results of the Phase 1b/2a clinical study of the Company’s independently developed glucagon-like peptide-1 receptor agonist, GZR18 Injection, in an obese/overweight population in China, along with the results of two other innovative insulins’ preclinical studies in poster presentations at the American Diabetes Association’s（ADA’s）84th Scientific Sessions.